Compare Inovio Pharmaceuticals Inc (INO) vs Marathon Petroleum Corp (MPC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Inovio Pharmaceuticals Inc vs Marathon Petroleum Corp — how do they compare? Inovio Pharmaceuticals Inc trades at $1.09 (market cap $89.27M), while Marathon Petroleum Corp trades at $316.89 (market cap $92.05B). The key difference: Marathon Petroleum Corp is far larger — about 1031.1× Inovio Pharmaceuticals Inc's market cap, and Marathon Petroleum Corp pays a 1.24% dividend while Inovio Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| INO | MPC | |
|---|---|---|
Market Cap | $89.27M | $92.05B |
Sector | Health | Energy |
52-Week High | $2.87 | $315.31 |
52-Week Low | $1.05 | $158.59 |
Enterprise Value | $60.28M | $124.23B |
Dividend Yield | — | 1.24% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
INO trades at $1.07, down 4.46% today, reflecting persistent bearish technical signals. The company shows minimal revenue of $65.34K (2025) with a net loss of $84.95M, resulting in a negative net margin of 130,000%. Despite beating recent EPS estimates, cash flow remains negative. Key near-term catalyst is the FDA's PDUFA decision on INO-3107 by October 30, 2026.
Outlook hinges on regulatory success for INO-3107; approval could drive significant upside, but failure poses substantial risk. High cash burn and lack of profitability underscore speculative nature. Analyst consensus is cautiously optimistic with 53% buy ratings, yet financial health remains precarious without near-term revenue growth.
Marathon Petroleum (MPC) trades at $317.00, up 1.41% today, reflecting strong momentum amid bullish technical signals and positive analyst sentiment. The stock shows robust fundamentals with a P/E of 20.58, P/S of 0.7, and ROE of 27.92%, supported by recent earnings beats in Q4 2025 and Q1 2026. Cash flow trends indicate operational strength with $8.25B from operations in 2025, while refining margins drive profitability, as highlighted in recent Zacks reports (July 2026).
Outlook remains positive with 76% analyst buy ratings and a consensus price target of $292.70, though risks include volatile energy markets and rising debt-to-asset ratios. The stock's proximity to resistance at $317 suggests potential consolidation, but sustained refining advantages and institutional support offer upside potential for investors focused on energy sector growth.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Inovio Pharmaceuticals Inc
Inovio Pharmaceuticals Inc is a United States based biotechnology company that develops active DNA-based immunotherapies and vaccines to treat and prevent cancers and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.
Read more on INO →About Marathon Petroleum Corp
Marathon Petroleum is an independent refiner with 13 refineries in the midcontinent, West Coast, and Gulf Coast of the United States with total throughput capacity of 2.9 million barrels per day. Its Dickinson, ND, facility produces 184 million gallons a year of renewable diesel. Its Martinez, CA, facility will have the ability to produce 730 million gallons a year of renewable diesel once converted. The firm also owns and operates midstream assets primarily through its listed MLP, MPLX.
Read more on MPC →
